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Abstract
Background: New Zealand Māori have a poorer outcome from breast cancer than non-Māori, yet prognostic data
are sparse. The objective of this study was to quantify levels of prognostic factors in a cohort of self-declared Māori
and European breast cancer patients from Christchurch, New Zealand.
Methods and Results: Clinicopathological and survival data from 337 consecutive breast cancer patients (27
Māori, 310 European) were evaluated. Fewer tumours were high grade in Māori women than European women (p
= 0.027). No significant ethnic differences were detected for node status, tumour type, tumour size, human
epidermal growth factor receptor, oestrogen and progesterone receptor (ER/PR) status, or survival.
In addition, tumour and serum samples from a sub-cohort of 14 Māori matched to 14 NZ European patients were
analyzed by immunohistochemistry and enzyme linked immunosorbent assay for molecular prognostic factors. Sig-
nificant correlations were detected between increased grade and increased levels of hypoxia inducible factor-1
(HIF-1a), glucose transporter-1 (GLUT-1), microvessel density (MVD) and cytokeratins CK5/6 (p < 0.05). High nodal
status correlated with reduced carbonic anhydrase IX (CA-IX). Negative ER/PR status correlated with increased
GLUT-1, CA-IX and MVD. Within the molecular factors, increased HIF-1a correlated with raised GLUT-1, MVD and
CK5/6, and CK5/6 with GLUT-1 and MVD (p < 0.05). The small number of patients in this sub-cohort limited discri-
mination of ethnic differences.
Conclusions: In this Christchurch cohort of breast cancer patients, Māori women were no more likely than
European women to have pathological or molecular factors predictive of poor prognosis. These data contrast with
data from the North Island NZ, and suggest potential regional differences.
Background
Breast cancer remains the most common malignancy in
New Zealand women, with over 2400 women diagnosed
each year [1]. The current trend of earlier detection, due
to regular mammography, and increased use of adjuvant
chemotherapy have improved breast cancer survival, yet
almost half of women with localised breast cancer
develop metastases [2] and over 600 women each year
in New Zealand die from their disease [1]. Standard
prognostic indicators for breast cancer, as recognized by
the National Cancer Institute in 1990, include lymph
node status, tumour size, nuclear grade, hormone
receptor status, tumour type, and human epidermal
growth factor receptor (Her2) status [3].
The lack of oxygen (hypoxia) in breast tumours has
been proposed as an additional prognostic and predic-
tive marker [4,5]. Tissue hypoxia leads to an adaptive
response regulated via hypoxia inducible factor-1 (con-
sisting of HIF-1a and HIF-1b)[ 6 ] ,a n dr a i s e dH I F - 1 a
levels have been associated with reduced survival, che-
motherapy failure, relapse and risk of metastases in
breast cancer [5,7,8].
Tissue banking to collect cancer tissue for research
was initiated in 1996 by clinicians and scientists at
Christchurch Hospital and University of Otago,
Christchurch [9]. The Cancer Society Tissue Bank
(CSTB) now holds tissue samples from over 4500 con-
sented cancer patients, including samples from over
1000 women with breast cancer. The collection of
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duced in 2003 [9]. Although the incidence rate of breast
cancer is reportedly similar across the two main ethnic
groups in New Zealand, age-standardised (World Health
Organisation) mortality rate of breast cancer is signifi-
cantly higher in Māori women (36.2/100 000) than in
non-Māori/non-Pacific women (mostly European, 24.5/
100 000) [10,11]. In addition, 5-year relative survival
ratios are reportedly lower in Māori (74%) than in non-
Māori/non-Pacific women (83% [12]).
The causes underlying the ethnic disparity in cancer
outcomes in New Zealand are unknown. High mortality
from all types of cancer in Māori have been attributed
to deprivation [13] and socioeconomic status [14], low
health care utilisation [12], and presence of risk factors
such as smoking and obesity [15]. Several national stu-
dies have demonstrated that Māori women had a higher
likelihood of disease spread at diagnosis [12-14,16]. It
has been suggested that the difference in stage at diag-
nosis, localised disease vs. regional or distant spread, is
one of the major factors contributing to the ethnic dis-
parity in mortality and survival [12,17]. However, a
report to the Ministry of Health has shown that adjust-
ing for stage at diagnosis accounted for only one third
o ft h es u r v i v a ld i f f e r e n c e[ 11]. A recent study of Auck-
land women with breast cancer suggested that Māori
women presented with a more aggressive disease (high
grade, large size tumours with increased lymph node
involvement) [18].
Internationally, there is increasing evidence that mole-
cular factors may be contributing to discrepancies in
cancer survival between different ethnicities [19]. For
example, African-American women tend to get breast
cancer at a much younger age and exhibit different
tumour characteristics, such as a negative hormonal
receptor status, which is frequently associated with posi-
tive axillary lymph node status even in small tumours,
and high nuclear grade [20-22]. In addition, Her2 status
in African American breast cancer patients did not pre-
dict outcome, unlike in European patients [22].
These reports have led us to investigate the clinico-
pathological and molecular features of breast cancer
patients with self-identified Māori and European ethni-
city within the Christchurch population.
Methods
Human ethics
Ethical approval for this study was granted by the Upper
South B Regional Ethics Committee, New Zealand
(Ethic approval numbers URB/05/08/102 and URB/06/
10/078). The use of tissue and serum samples donated
to CSTB was approved by the CSTB Board. All partici-
pants have given written informed consent.
Breast cancer patients
As ethnicity data collection was first implemented on
the 12
th of May 2003 [9], data from all female breast
cancer patients who have gifted tissue to the CSTB
between 12
th of May 2003 and 31
st of December 2007
was investigated. Follow-up was recorded until 14
th of
September 2009. The tissue banking consent form offers
the declaration of ethnicity according to the New Zeal-
and Census (2001/2006) format, and as such includes
individuals with multiple ethnic affiliations. For this
study, a prioritised ethnic classification system was used
where individuals were classified as Māori if Māori was
self-reported as one of the ethnic groups in any ethni-
city field. Of the 443 female breast cancer patients on
the CSTB database for this time period, 67 did not sup-
ply ethnicity data, and 20 were of other ethnicities
representing groups too small to be analysed separately,
and were thus excluded. Patients with ductal carcinoma
in situ (DCIS) but no invasive carcinoma (n = 12), and
patients with evidence of prior cancer (breast or other,
according to their medical notes, n = 7), were also
excluded. Of the remainder, 310 women were self-
declared European (including NZ European and Other
European) and 27 women were self-declared Māori
(including 17 sole Māori, i.e. those who identified with
no other ethnicity). Ethnicity of the cohort is shown in
Table 1.
Breast cancer treatment
All patients were treated following standard protocols
within the Surgical and Oncology Services at Christch-
urch Hospital, facilitated by a weekly Breast Multidisci-
plinary Team Meeting. Following fine needle aspirate
(FNA) or core biopsy diagnosis of breast cancer, women
were staged with full blood count, biochemistry profile,
and chest X-Ray. Those with clinically or pathologically
determined extensive axillary lymphadenopathy, locally
advanced disease, or abnormal signs, or symptoms sus-
picious of distant metastatic disease, underwent CT ima-
ging of chest, abdomen and pelvis, and nuclear medicine
bone scan, to rule out distant metastases. Breast surgery
was wide local excision or simple mastectomy, with
elective immediate reconstruction for node-negative
women according to patient preference. At least level 2
axillary dissection or sentinel lymph node dissection fol-
lowed by level 2 dissection for an involved sentinel node
was carried out in all women. Staging was by American
Joint Committee on Cancer (AJCC) TNM classification
[23]. Radiation therapy was routinely given for invasive
disease exceeding 40 mm diameter, 4 or more axillary
nodes involved, or involved deep margins. Radiation fol-
lowed chemotherapy if both modalities were given.
Adjuvant chemotherapy was offered to all fit women
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using standard anthracycline/cyclophosphamide combi-
nation regimens with or without paclitaxel. Trastuzu-
mab was added for women with HER2 positive tumours
(IHC3+ or FISH amplified) following the FinHER proto-
col [24] according to funding by New Zealand’sP H A R -
MAC drug funding agency. Adjuvant hormonal therapy
was given for all oestrogen and/or progesterone receptor
positive tumours, for a minimum of 5 years. Tamoxifen
was used for pre- and peri-menopausal women and aro-
matase inhibitors following menopause, confirmed using
blood hormone levels. Follow-up was by clinical exami-
nation, 3-monthly for 2 years, then 6-monthly, with
annual mammography.
Māori-NZ European sub-cohort
A smaller sub-cohort of patients was selected for mole-
cular studies. Breast cancer patients in the CSTB data-
base, who had identified themselves as Māori, and who
had sufficient and appropriate biological material for
molecular analysis, were identified for this study. For
each self-declared Māori patient, the closest match by
clinicopathological data was chosen from those identify-
ing themselves as NZ European. The characteristics of
the patients that were used to match were, in order of
priority: age (< 50 years or ≥ 50 years), histological type
of tumour, lymph node status, oestrogen and progester-
one receptor (ER and PR) status. A total of 14 Māori
and 14 NZ European patients were identified, consisting
of: 6 pairs under and 8 pairs over 50 years of age; 9
pairs with ductal carcinoma, 2 pairs with mixed ductal/
lobular carcinoma, 1 pair with mixed ductal/tubular car-
cinoma and 2 mismatched pairs; 6 pairs with node nega-
tive disease, 5 pairs with 1-3 nodes involved, 1 pair with
more than 3 nodes involved, and 2 mismatched pairs;
11 pairs with ER positive tumours, 2 with ER negative
tumours and 1 mismatched pair; 10 pairs with PR posi-
tive tumours, 2 with PR negative tumours and 2 mis-
matched pairs.
Clinicopathological data
Clinicopathological data from all 27 self-declared Māori
patients and 310 self-declared European patients were
analysed for the following characteristics: patient age,
histological tumour type (ductal, lobular and mixed),
maximum tumour size (mm), grade (1-3), metastasis to
the lymph nodes (node status: N0, N1-3, N > 3), Not-
tingham Prognostic index (NPI = (tumour size (cm) ×
0.2) + grade + node status) [25]). Grade was re-analysed
by a specialist breast pathologist (GCH), blinded to eth-
nicity, prior histology reports and clinical data, for a
random subset of patients (n = 15) from both ethnicities
and was confirmed in all. Recommendations for report-
ing tumour prognostic factors were followed [26].
Immunohistochemistry
Diagnostic immunohistochemistry (IHC) had been per-
formed on samples for ER (1/200, Labvision, Hallam,
Australia), PR (1/200, Novocastra, Newcastle Upon
Tyne, UK) and Her2 status (Hercep test, Dako,
Christchurch, NZ), as appropriate. Equivocal Her2 status
was confirmed by FISH (LabPlus, Auckland, NZ).
Tissue sections for additional IHC of the sub-cohort
were selected from H&E stained diagnostic slides by a
specialist pathologist. Corresponding formalin-fixed, par-
affin-embedded tumour tissue blocks were cut, deparaf-
finised and rehydrated, followed by EDTA antigen
retrieval, using standard anatomical pathology proce-
dures. Immunohistochemistry was performed on serial
3-4 μm thick sections.
IHC was performed using Cell and Tissue Staining
Kits (R&D Systems, Minneapolis, MN, USA) for HIF-1a
(1/25, BD Biosciences, San Jose, CA, USA), CA-IX (1/
2000, Novus Biologicals, Redfurn, Australia), Glut-1 (1/
200, Abcam, Cambridge, UK), cytokeratins CK5/6 (1/50,
Zymed, San Francisco, USA), and CD31 (1/40, Dako,
Christchurch, NZ) following manufacturers’ protocols.
Staining was followed by automated counterstaining
with hematoxylin (Leica Autostainer XL). Two slides
Table 1 Ethnicity data of breast cancer patients
Self-declared Ethnicity No. Ethnic classification
Māori 16 Māori
Māori/Indian or NZ European/Māori or NZ European/Māori/Kiwi 11 Māori
NZ European 290 European
Other, American Caucasian or American Irish or British or Dutch or English or European or German or Irish or
New Zealander or Scottish or Russian or NZ European/British or Dutch
20 European
Other, Filipino or Thai or Australian or Malaysian Chinese or Chinese 15 excluded
Samoan or NZ European/Samoan 5 excluded
No ethnicity stated 67 excluded
Total 424 27 310 (87)
Ethnicity data of female breast cancer patients who gifted tissue to the Cancer Society Tissue Bank between May 2003 and December 2007.
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pathologist on two separate occasions, according to sta-
tistical advice.
Quantification of IHC
Receptor status data was available through the CSTB
database, and presented as follows: QuickScore (QS) as
a score out of 8 measuring intensity and area [27], and
Histoscore (H-score) as a score out of 300: intensity of
staining on a scale of 0-3, and a percentage (0-100) area
stained [28]. For statistical analysis Her2 status was
separated into positive or negative, and ER/PR status
was separated into negative (QS = 0, H-score = 0),
weak/moderate positive (QS = 1-6, H-score = 1-150)
and strong positive (QS = 7-8, H = 151-300).
Immunostaining was evaluated by an independent
pathologist who was blinded to patient clinico-patholo-
gical data, including ethnicity. IHC staining for all
hypoxia markers was quantified using H-score. For HIF-
1a, only staining of the nucleus of tumour cells was
considered. Cytoplasmic and membrane staining of
tumour cells was considered for Glut-1 and CA-IX.
Cytokeratin CK5/6 staining was scored as positive or
negative. Microvessel density (MVD) according to CD31
positive cells was quantified as described before [29].
Briefly, slides were scanned at low power (x40-100) for
three areas of highest vascularity, then were examined at
high power (x250-400) and placed into high vs. med-
ium/low categories.
Immunoassay of serum samples
VEGF-A and IGF-1 levels in serum samples of the sub-
cohort of breast cancer patients were measured using
Quantikine Human Immunoassay kits (R&D Systems),
following manufacturer’s recommendations. Serum sam-
ples were assayed in duplicate on two separate occasions
with associated standards as controls. Of the corre-
sponding tumour samples, 22/28 breast cancer serum
samples in the sub-cohort were available for analysis.
Statistics
For the entire cohort, ER and PR status (negative, weak
to moderate and strong positive) in the two ethnic
groups was compared using chi-square tests for contin-
gency tables. Ordinal categories were compared using
proportional odds logistic regression. If the proportional
odds assumption was violated, a Cochran-Armitage test
for trend was used. Continuous variables were compared
using t-tests. Tumour size had a skewed distribution and
so both square root and log transformations were
explored. Patient survival was calculated from the date
of primary surgery to the date of death or the last fol-
low-up according to the Kaplan-Meier method. Disease-
free survival was calculated similarly with date of
detection of metastases as the endpoint. Differences in
survival distributions were evaluated by a log-rank test.
Values of p < 0.05 were considered significant.
For the matched subcohort, comparisons between the
two ethnic groups used paired t-tests for continuous vari-
ables, McNemar’s test for the significance of changes for
binary variables and Bowker’s test of symmetry for
ordered categories. Within the matched-cohort it was
necessary to take account of the matching when examin-
ing relationships between clinico-pathological variables
and serum- and tumour-associated factors, and correla-
tions among the serum- and tumour-associated factors.
This was done by treating each matched pair as a cluster
and carrying out analyses in SUDAAN using jackknifing
to obtain appropriate standard errors and p values.
All other analyses were carried out in SAS 9.1.
Results
Breast cancer patient cohort
During the period of 2003-2007 the CSTB had accumu-
lated samples gifted from 357 breast cancer patients with
associated ethnicity data (Table 1). Data showed that
7.6% of breast cancer donors identified themselves as
Māori and 86.8% as European (NZ European and other
European). Mean age at diagnosis of Māori patients was
3.4 years younger than that of European patients, but this
was not significant (p = 0.63) (Table 2).
A higher proportion of Māori patients presented with
grade 2 than grade 3 tumours, whereas a similar propor-
tion of European patients had grade 2 and 3 tumours.
Māori patients had odds ratio of 0.4 of European
patients of a higher grade tumour (p = 0.027) (Table 2).
A marginal difference in ER status between Māori and
European patients was apparent (p = 0.095), with a ten-
dency for Māori patients to have a positive ER status.
Similar proportions of tumours were negative, weak or
positive for PR, with no ethnic differences. No differ-
ences in node status, histological tumour type, maxi-
mum tumour size or NPI were apparent between the
two ethnicities. However, European women had
tumours on average 2.1 mm smaller than Māori women,
and a lower percentage with any positive nodes (47.2%
vs. 60.0%) (Table 2).
Her2 status had not been determined for 46% of all
tumours, in accordance with local protocols at the time.
Her2 status was known for 95% of patients under 50
years of age, and for 41% of patients over 50 years of
age. Of those patients with known Her2 status (n = 186)
the intrinsic subtypes were as follows: 1 Māori and 34
European were triple negative (Her2-, ER/PR-), 13
Māori and 111 European were luminal A (Her2-, ER
and/or PR+), 1 Māori and 13 European were luminal B
(Her2+, ER and/or PR+), and 1 Māori and 12 European
were Her2 (Her2+, ER/PR-).
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women was similar (1085 and 1061 days, respectively).
Four Māori patients and 42 European patients had died
during follow-up, and 3 Māori and 50 European women
had a recorded recurrence or metastasis during follow
up (up to 14
th September 2009). Kaplan-Meier survival
analysis showed no significant difference in overall sur-
vival (log rank, p = 0.86) (Figure 1) or disease-free survi-
val (log rank, p = 0.50) (Figure 2) between Māori and
European breast cancer patients. Median survival was
not reached, i.e. more than 50% of the cohort were alive
and/or disease-free at the end of follow up. No further
recurrences were observed in the Māori group after 556
days following surgery, while metastases continued to be
recorded in the European group for up to 2028 days.
Death in Māori women was recorded up to 1323 days
after surgery, and for up to 1969 days in European
women. The low number of Māori patients who had
recorded recurrence/metastasis or death (total n = 5)
limited significant conclusions.
Molecular data in sub-cohort of breast cancer patients
Due to careful matching, there were no significant eth-
nic differences by clinicopathological criteria in the sub-
cohort (n = 28). Due to low patient numbers in this
sub-cohort, ethnic differences could not be clarified, and
no statistically significant differences were observed
between the two ethnic groups for IHC staining for
either intrinsic hypoxia markers (HIF-1a p = 0.98,
GLUT-1 p = 0.69, CA-IX p = 0.61), or microvascular
density (p = 0.65), or cytokeratins (CK5/6 p = 0.65) in
tumours (Table 3). Similarly, there were no significant
Table 2 Clinicopathological characteristics of breast cancer patients
Measure European
(n = 310)
Māori
(n = 27)
Ethnic difference
(95% CI)
Statistical test
1 Test value df p
Age
(years)
mean 61.1
(sd 14.4)
mean 57.7
(sd 13.3)
3.4 years
(-2.2, 9.1)
t test 1.19 335 0.63
Ductal 74.2% (230) 66. 7% (18) % ductal ductal vs rest c
2 0.72 1 0.39
Lobular 14.8% (46) 22.2% (6) 7.5%
Other 11.0% (34) 11.1% (3) (-10.9, 26.0)
Unknown 00
Tumour
size (mm)
mean 21.5
(sd 13.2)
mean 23.6
(sd 14.4)
-2.1 mm
(-7.3, 3.2)
t test -0.78 332 0.43
unknown 30
Grade: 1 13.0% (40) 18.5% (5) % Grade 3 vs 1 or 2 Wald c
2 4.77 1 0.027*
2 43.7% (134) 63.0% (17) 24.8%
3 43.3% (133) 18.5% (5) (9.1, 40.5)
unknown 30
Node: N0 52.8% (160) 40.0% (10) Any +ve Wald c
2 1.73 1 0.19
N1-3 31.0% (94) 36.0% (9) -12.8%
N>3 16.2% (49) 24.0% (6) (-32.8, 7.2)
unknown 72
NPI mean 4.4
(sd 1.3)
mean 4.3
(sd 1.4)
0.05
(-0.5, 0.6)
t test 0.18 326 0.85
unknown 72
ER: -ve 19.7% (60) 11.5% (3) % Strong Wald c
2 2.78 1 0.095
weak +ve 10.8% (33) 0% (0) -19.0%
strong +ve 69.5% (212) 88.5% (23) (-32.3, -5.6)
unknown 51
PR: -ve 31.0% (94) 23.1% (6) % Strong Wald c
2 1.65 1 0.20
weak +ve 36.0% (109) 30.8% (8) -13.2%
strong +ve 33.0% (100) 46.1% (12) (-33.0, 6.7)
unknown 71
Her2: +ve 15.0% (25) 12.5% (2) % +ve c
2 0.07 1 0.79
-ve 85.0% (142) 87.5% (14) 2.5
unknown 143 11 (-14.6, 19.6)
Clinicopathological characteristics of all Māori and European female breast cancer patients who gifted tissue to the Cancer Society Tissue Bank between May
2003 and December 2007 (sd = standard deviation, df = degrees of freedom). *significant at p < 0.05.
1 t test for two independent samples (pooled variance as no indication from folded F of unequal variances), c
2 from chi-square test for contingency tables, Wald
c
2 from ordinal logistic regression for which the proportional odds assumption was not violated.
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and NZ European cancer patients for either VEGF-A (p
= 0.10) or IGF-1 (p = 0.27).
HIF-1a was expressed in 93% of the breast tumours,
and all samples showed some degree of GLUT-1 and
CA-IX staining. In tumour and vascular endothelial
cells, both nuclear and cytoplasmic staining of HIF-1a
was observed, as well as patchy, diffuse and increased
staining adjacent to necrosis, but only nuclear staining
of tumour cells was quantified. GLUT-1 and CA-IX
staining showed patchy as well as increased expression
adjacent to necrosis. CK5/6 staining was very low or
absent in most tumour samples. High microvascular
density was detected in 40% of samples.
Comparisons of molecular factors and clinicopatholo-
gical details showed several significant relationships
(Table 4). High nodal status correlated with reduced
CA-IX (p = 0.0068). Grade showed a positive association
with HIF-1a (p = 0.0064), GLUT-1 (p = 0.013), MVD
(0.0009) and CK5/6 (p = 0.0069). Negative ER status
was associated with increased GLUT-1 (p = 0.046) and
high MVD (p = 0.038). PR status showed similar asso-
ciations with GLUT-1 (p = 0.024), CA-IX (p = 0.018)
and MVD (p = 0.013).
A comparison among molecular factors showed strong
positive correlations between HIF-1a a n dG l u t - 1( p=
0.001), MVD (p = 0.01), and CK5/6 (p = 0.002). CK5/6
correlated positively with Glut-1 (p < 0.0001) and MVD
(p = 0.001) (Table 5).
Circulating molecular factors in serum did not show
significant associations with any clinicopathological or
tumour associated factors. However, VEGF-A concen-
trations tended to be higher in patients with PR positive
tumours (p = 0.069), and IGF-1 higher in ER/PR posi-
tive tumours (p = 0.075/0.074) (Table 4).
Median follow-up time for Māori and NZ European
women in the sub-cohort was similar (1227 and 1281
days, respectively). Of the 14 Māori patients, 3 died
within the follow-up period, whereas none of the NZ
European patients died. Two of the NZ European
women had a recorded metastasis in the follow-up per-
iod, but none of the Māori women did.
Discussion
Analysis of clinical, pathological and molecular data of
the CSTB cohort of breast cancer patients found no evi-
dence of worse prognostic indicators in self-declared
Māori compared to self-declared European women.
Figure 1 Breast cancer survival in Māori and European women. Survival from surgery to death from any cause by Kaplan-Meier survival
analysis of Māori (n = 27, grey) and European (n = 310, black) women with breast cancer.
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cancer patients presented with significantly lower grade
tumours than European breast cancer patients, which is
in contrast to other published reports from elsewhere in
New Zealand [11,12,18,30,31].
Specifically, a recent report by the Auckland Breast
Cancer Study Group showed that NZ Māori participants
(n = 133) had higher grade tumours than European par-
ticipants (n = 1220) [18]. Weston et al. also demon-
strated that NZ Māori participants had larger tumours
Figure 2 Disease-free survival of Māori and European women with breast cancer. Kaplan-Meier survival analysis of Māori (n = 27, grey) and
European (n = 310, black) women with breast cancer.
Table 3 Molecular data of Māori and NZ European sub-cohort of breast cancer patients
Māori
no.
Māori NZ European
no.
NZ European Mean difference
(95% CI)
t
a df
b p
HIF-1a
H-score
c
14 75.5 (± 55.5) 14 75.2
(± 58.9)
0.36
(-34.4, 35.1)
0.02 13 0.98
GLUT-1
H-score
c
14 112.9 (± 45.2) 14 120.4 (± 46.4) -7.5
(-47.6, 32.6)
-0.40 13 0.69
CA-IX
H-score
c
14 56.6 (± 32.6) 14 64.0
(± 59.1)
-7.4
(-37.7, 22.9)
-0.53 13 0.61
MVD
high/low
d
14 5/14
(35.7%)
14 6/14
(42.9%)
7.2% 0.2 1 0.65
CK5/6
pos/neg
d
14 2/14
(14.3%)
14 3/14
(21.4%)
7.1% 0.2 1 0.65
VEGF-A
pg/ml
c
11 299.9 (± 162.7) 11 359.6 (± 174.8) -59.8
(-134, 14.5)
-1.79 10 0.10
IGF-1
ng/ml
c
11 114.5 (± 31.4) 11 100.6 (± 24.7) 14.0
(-12.4, 40.4)
1.18 10 0.27
a t from a t-test for paired samples or S from McNemar’s test for significance of changes
b degrees of freedom
c mean (± sd)
d frequency (%) high/positive
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pants [18], which is supported by an analysis of prog-
nostic factors of 21,586 breast cancer cases in the New
Zealand Cancer Registry, showing that tumours in
Māori women were more likely to be larger, less well
differentiated (grade), Her2 positive, and ER and PR
negative than tumours in non- Māori/non-Pacific
women [31]. Our data showed no significant difference
in tumour size (upper 95% CI showed a difference of
7.3 mm) which could have indicated a difference in
delay in presentation. Node status, which could have
indicated a difference in extent of disease spread, was
not significantly different either, although 95% CI were
well within the estimates from national studies [18,31].
Receptor status was somewhat more favourable for
Māori women and not compatible with a major disad-
vantage for them. Survival did not differ between the
two ethnicities during the limited follow-up period,
which is in accord with our clinicopathological and
molecular data.
T h em a j o r i t yo ft u m o u r s( w i t hk n o w nH e r 2s t a t u s )
from both ethnicities were intrinsic subtype luminal A.
Table 4 Molecular data of matched Māori and European sub-cohort of breast cancer patients arranged by predictive
clinicopathological factors
Measure
(n=)
HIF-1a
H-score
Mean
(± sd)
GLUT-1
H-score
Mean
(± sd)
CA-IX
H-score
Mean
(± sd)
MVD
frequency
high
(%)
CK 5/6
frequency
positive
(%)
VEGF-A
pg/ml
Mean
(± sd)
IGF-1
ng/ml
Mean
(± sd)
Nodal status
1 0.073 0.22 0.0068 0.65 0.10 0.40 0.77
N0 (12) 44.38
(± 27.08)
107.08
(± 43.47)
63.65
(± 24.79)
1/12
(8.33%)
1/12
(8.33%)
323.39
(± 167.41)
103.2
(± 22.27)
N1 (12) 100.21
(± 67.46)
131.88
(± 46.19)
64.17
(± 67.78)
8/12
(66.7%)
4/12
(33.33%)
370.00
(± 189.65)
109.93
(± 35.57)
N2 (4) 93.75
(± 47.72)
99.38
(± 42.93)
38.75
(± 7.77)
2/4
(50%)
0/4
(0.0%)
230.13
(± 50.22)
114.67
(± 32.40)
Grade
1 0.0064 0.013 0.075 0.0009 0.0069 0.15 0.29
1 (5) 41.5
(± 19.57)
108.50
(± 31.60)
72.5
(± 19.04)
0/5
(0.0%)
0/5
(0.0%)
348.75
(± 126.36)
102.03
(± 21.77)
2 (13) 50.96
(± 36.29)
94.23
(± 37.63)
42.31
(± 16.09)
2/13
(15.38%)
0/13
(0.0%)
401.92
(± 209.77)
119.19
(± 34.50)
3 (10) 124.0
(± 58.47)
149.75
(± 42.22)
77.63
(± 72.38)
9/10
(90.0%)
5/10
(50%)
236.67
(± 89.36)
97.92
(± 22.48)
ER status
1 0.18 0.046 0.052 0.038 0.18 0.14 0.075
Negative (5) 131.50
(± 70.83)
142.0
(± 53.19)
120.50
(± 73.56)
5/5
(100%)
2/5
(40%)
245.98
(± 109.29)
87.49
(± 17.57)
Positive (23) 63.15
(± 45.72)
111.09
(± 42.43)
47.23
(± 26.94)
6/23
(26.09%)
3/23
(13.04%)
354.38
(± 176.18)
113.46
(± 28.75)
PR status
1 0.15 0.024 0.018 0.013 0.059 0.069 0.074
Negative (6) 122.08
(± 67.42)
151.25
(± 52.70)
118.13
(± 66.05)
6/6
(100%)
3/6
(50%)
237.44
(± 99.96)
90.77
(± 17.66)
Positive (22) 62.61
(± 46.72)
107.16
(± 38.92)
44.54
(± 24.22)
5/22
(22.73%)
2/22
(9.09%)
364.36
(± 176.92)
113.85
(± 29.64)
1Overall comparisons of outcomes for categorical predictors are shown; significant comparisons are shown in bold (p < 0.05). Analysis took account of the paired
design by treating each pair as a cluster and using jackknifing of clusters, in SUDAAN.
Table 5 Associations of tumour and circulating factors in breast cancer patients
Correlations
1 GLUT-1 CA-IX MVD CK5/6 VEGF-A IGF-1
HIF-1a r(p) 0.66(0.001) 0.45(0.27) 0.57(0.01) 0.59(0.002) -0.16(0.45) -0.15(0.63)
GLUT-1 r(p) 0.40(0.11) 0.38(0.03) 0.73(< 0.0001) 0.06(0.82) -0.00(0.98)
CA-IX r(p) 0.25(0.36) 0.34(0.27) 0.01(0.95) -0.35(0.23)
MVD r(p) 0.58(0.001) 0.41(0.10) 0.29(0.18)
CK5/6 r(p) 0.27(0.12) 0.17(0.12)
VEGF-A r(p) -0.03(0.96)
Associations of tumour-associated (HIF-1a, GLUT-1, CA-IX, MVD, CK5/6) and circulating (VEGF-A, IGF-1) factors in sub-cohort of breast cancer patients (n = 28).
Pearson product moment correlations, 2-tailed, reported as r, with p in brackets, significant correlations are shown in bold p < 0.05 (VEGF-A n = 22, andI G F - 1n
= 21).
1Analysis took account of the paired design by treating each pair as a cluster and using jackknifing of clusters, in SUDAAN.
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in different ethnic groups in the US had been reported
[32]. Compared to Caucasians, African Americans
showed a higher, whereas Japanese showed a lower pre-
valence of basal-like breast tumour subtype (triple nega-
tive and cytokeratin 5/6+ and/or HER1+), with
associated poorer prognosis for African American
women and better prognosis for Japanese women [32,33].
Clearly, the main limitation of our study is the small
number of patient samples (n = 337). The constraint is
due to availability of samples from breast cancer
patients who identified themselves as Māori (n = 27).
Molecular research is of concern for indigenous people,
and needs to be carried out with cultural sensitivity. In
New Zealand, Māori traditionally consider that human
tissue and the information derived from it, is collectively
owned by the whānau (family), hapū (sub-tribe) and iwi
(tribe). Hence, tissue donation may require iwi and whā-
nau approval. The accrual of Māori samples by the
CSTB, which holds the largest collection of tumour
samples for research in New Zealand, is considered an
achievement [9,10]. The samples analysed in this study
represent all available samples from Māori breast cancer
patients since accurate ethnicity data collection was
introduced in 2003 up to the end of 2007.
This study was performed specifically with breast can-
cer patients treated through Christchurch Hospital in
Canterbury, South Island NZ. Reports into ethnic
inequalities in cancer mortality do not report data by
region [11] and studies into regional inequalities in can-
cer mortality do not report ethnicity data [34]. The
Ministry of Health’s Atlas of Cancer Mortality (1994-
2000) has ‘insufficient’ ethnicity data (’less than 16 can-
cer deaths over 7 year time period’)a tt h el e v e lo fD i s -
trict Health Board for most of the South Island for most
cancer types, and no regional data on breast cancer
mortality by ethnicity is available for Canterbury [35].
Hence, as 87% of Māori live in the North Island [36], all
national data on ethnic inequalities in cancer incidence,
mortality and survival are necessarily shaped by data
from the North Island. This may partly explain why our
data differs from previous publications, but also urges
further research into potential regional variability.
It is of note that most published epidemiological data
on breast cancer have utilised the New Zealand Cancer
Registry data set. A recent paper has quantified the dis-
crepancy between ethnicity data of the registry and cen-
sus statistics between 1981 and 2004 [37]. Māori were
initially undercounted by as much as 31% in the registry
compared to self-reported data, but even the 2001 data
showed undercounting of Māori by 15%. Hence most
recent studies incorporate adjustment factors to take
account of undercounting (e.g. [15]).
The selection of breast cancer patients may account for
differences in the studies. All patients attending the
Christchurch Hospital pre-admission clinic, prior to can-
cer surgery, are considered potential donors, and are
given the opportunity to donate part of their tumour to
research [9]. However, the CSTB currently only consents
breast cancer patients who attend Christchurch Hospital,
and not those who are treated through the private sector.
In addition, only patients who have operable cancers of
sufficient size are consented, and only tumour samples
excess to diagnosis can be banked, thus possibly selecting
for larger tumours. On the other hand, the percentage of
patients who identified themselves as Māori in this study
(7.4%) compared well with the New Zealand census data
for the Canterbury region, which showed that 7.2% of
people identified themselves as Māori [38], indicating
that this cohort is representative of the region.
This is the first study to analyse hypoxia-related prog-
nostic factors in a sub-cohort of Māori breast cancer
patients. Due to low numbers it could not clarify ethnic
differences between the groups. However, it demon-
strated significant associations between clinicopathologi-
cal data and several molecular factors in tumours and
serum across both ethnicities, confirming their strong
predictive value even in this small cohort. A significant
association of CK5/6 with microvessel density and
hypoxia (HIF-1a and GLUT-1) was detected, a first
report to our knowledge. Presence of CK5/6 is a hall-
mark of basal-like carcinoma, which is an aggressive
form of breast cancer with, reportedly, the worst prog-
nosis of all molecular breast cancer subtypes [39,40].
However, the prognostic significance of CK5/6 expres-
sion is controversial, as some studies have shown that
poor prognosis was determined by ER absence and not
b yC K 5 / 6e x p r e s s i o n[ 4 1 ] .I nag r o u po f3 0h e r e d i t a r y
breast cancer patients, an association between HIF-1a
and CK5/6 was indicated, but did not reach significance
[42]. Our study did not confirm the reported association
between CK5/6 and CA-IX [43].
Correlations detected in this study of hypoxia markers
with nodal status and grade confirm previous studies in
breast cancer [e.g. [44,45]]. Our study supported an
inverse relationship between tumour hypoxia and hor-
mone receptor status, although the relationship between
hypoxia markers and ER status remains controversial
[46-49].
Conclusions
This study could find no evidence of poorer prognostic
indicators in Māori compared to European women with
breast cancer in the Canterbury region, suggesting regio-
nal differences within New Zealand. As regional ethni-
city data on cancer is extremely sparse, further studies
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Page 9 of 11are warranted. Future studies are supported by the
launch in August 2009 of the Christchurch Breast Can-
cer Patient Register. Our data may also assist a recent
memorandum of understanding which was signed
between Manawhenua ki Waitaha, a representative col-
lective of the seven NgāiT a h uR ūnanga (Māori tribal
organisation/authority), and the Canterbury District
Health Board to assist in improving the health outcomes
for the Canterbury Māori population [50].
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